Eton Pharmaceuticals (NASDAQ:ETON) Insider David Krempa Sells 25,000 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 25,000 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the transaction, the insider owned 37,025 shares of the company’s stock, valued at $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total transaction of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $64.43 on Tuesday. Eton Pharmaceuticals, Inc. has a 52-week low of $14.27 and a 52-week high of $66.37. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The firm’s fifty day moving average is $42.81 and its 200 day moving average is $30.69. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 169.55 and a beta of 0.86.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post 0.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC raised its position in Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after purchasing an additional 217,042 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock valued at $2,274,000 after buying an additional 45,341 shares during the period. Jane Street Group LLC boosted its position in shares of Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after buying an additional 31,596 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Eton Pharmaceuticals by 114.5% during the second quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock valued at $3,457,000 after buying an additional 129,467 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $41,000. 27.86% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ETON has been the topic of several analyst reports. B. Riley Financial reissued a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Zacks Research cut Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Craig Hallum boosted their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group increased their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $67.50.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.